AF Found by Accident at a Routine Check

If you have just been diagnosed with atrial fibrillation and there is a life insurance application waiting, the question underneath your worry is usually this: will an insurer price the AF for itself, or as a stand-in for the risk of a stroke? The honest answer is mostly the second. Atrial fibrillation is rarely treated as a condition that directly shortens life. It is treated as a marker — of stroke risk, and sometimes of an underlying heart problem — and almost everything an underwriter asks about AF is really an attempt to size those two things.

That reframing matters, because it explains why the outcome is usually far better than the diagnosis feels at first. Life insurance with atrial fibrillation in the UK is, for most people, assessed rather than refused. An irregular heartbeat that is well controlled, with no dangerous structure found behind it and stroke risk being managed, is a risk the market is comfortable pricing. Being on an anticoagulant does not count against you as a penalty — if anything it tells the underwriter the risk is being actively handled.

The short answer: rated as a stroke marker, not a death sentence

Atrial fibrillation is the most common sustained heart rhythm disturbance in the UK, and one of the significant contributors to stroke — which is the single most important fact for understanding how it is underwritten. An underwriter is not frightened of an irregular pulse in itself. What they are pricing is the increased chance of a stroke that AF can carry, and the possibility that the AF is a signal of some other heart condition sitting behind it.

Source: British Heart Foundation, UK Cardiovascular Disease Factsheet (July 2026).

Read that way, the assessment stops being mysterious. Almost every question you will be asked is aimed at one of two targets: how high is the stroke risk, and is there structural heart disease? A person with well-controlled AF, a normal scan of the heart and stroke risk managed by medication presents a very different picture from someone whose AF turned up alongside heart failure or valve disease. Both are described by the same two words, and they can receive very different terms — which is exactly why the label alone tells an underwriter so little.

Priced for itself, or as a stroke proxy?

The reason this distinction is worth spelling out is that it changes what you should expect to happen. If AF were priced as a directly life-shortening disease, the diagnosis alone would drive the terms. Because it is largely priced as a proxy for stroke risk and for underlying heart disease, the diagnosis is only the beginning, and your individual risk factors do most of the work.

That is why an underwriter cares about your blood pressure, your age, whether you have diabetes, whether you have ever had a stroke or a mini-stroke, and whether a scan found anything structural. These are the ingredients of stroke risk that clinicians themselves weigh — the formal stroke-risk scoring your own doctor uses to decide on anticoagulation is built from the same factors. The insurer is, in effect, looking over your clinical team's shoulder at the same risk assessment, and pricing from it.

This is the same discipline underwriters apply across the board: they assess the specifics, not the headline word. It is the reason a term like "in remission" carries almost no information on its own, as our page on why "in remission" means nothing to an underwriter explains. Atrial fibrillation works the same way. "I have AF" is the start of the conversation; the terms come from what sits underneath it.

What UK insurers actually ask about AF

Expect a focused set of questions, each of which maps onto stroke risk or underlying disease. The first is the pattern: is your AF paroxysmal — coming and going and stopping on its own — or persistent, or permanent? Paroxysmal AF that is infrequent and well tolerated often reads more favourably than continuous AF, though the rest of the picture still governs the outcome.

Then comes the cause. Was a reason found — high blood pressure, an overactive thyroid, a valve problem, sleep apnoea, heavy alcohol use — or was none identified? An underwriter will want to know because a treatable cause that has been addressed is reassuring, while structural heart disease raises the stakes. Expect questions about your control: whether you are on a rate-control or rhythm-control approach, whether it is stable, and whether you still get symptoms such as palpitations, breathlessness or dizziness.

Treatment history sits in the same category. If you have had a cardioversion to reset the rhythm, or a catheter ablation to correct the electrical problem, the underwriter will want to know when, and whether it held. A successful procedure that has kept you in a normal rhythm is a point in your favour, though insurers usually want to see a period of stability afterwards rather than assessing you in the first weeks. As with the medication, the question is not whether you have been treated but whether the treatment has settled the risk.

Finally, the investigations. What did your ECG show, and crucially what did an echocardiogram — an ultrasound scan of the heart — reveal about its structure and function? What were your thyroid results? Much of this already sits in your GP and hospital records, and an insurer can ask to see a targeted report with your written consent. Understanding what a life insurer can and cannot see in your medical record is worth doing before you apply, because the report will often confirm the very details you are being asked about.

What an anticoagulant does to the assessment

Many people newly on warfarin or, more commonly now, a direct oral anticoagulant such as apixaban, rivaroxaban, edoxaban or dabigatran, assume the drug is a black mark. It is not, and the logic is worth holding onto. An anticoagulant tells the underwriter two things: that your clinical team judged your stroke risk high enough to warrant treatment, and that the risk is now being actively reduced. The first is part of the picture; the second is genuinely in your favour.

So insurers do not penalise the medicine as such. They ask which anticoagulant you take, how long you have taken it, and whether things are stable — and for warfarin specifically, whether your monitoring (the INR blood test that keeps the dose in range) is settled. A stable, well-monitored anticoagulant regime supports the case that your stroke risk is controlled. Stopping the medication before applying, in the hope the form looks cleaner, would be a serious mistake: it removes the very thing that is managing the risk, and an underwriter reads an untreated high stroke risk far less kindly than a treated one.

There is one honest caveat worth flagging if you have an active outdoor life. Being on an anticoagulant raises bleeding risk, which can matter where a hobby carries a real chance of injury — something an insurer weighs when it tiers an activity, as our page on how climbing and mountaineering are assessed on a life application sets out. It does not make cover unavailable; it is simply one more specific the underwriter takes into account alongside the AF itself.

Newly diagnosed and mid-investigation

A recent diagnosis often means you are still in the middle of tests — waiting for an echocardiogram, a cardiology follow-up, or thyroid results — and this creates a genuine dilemma about timing. Apply now, and the insurer may be assessing an incomplete picture; wait, and you are without cover in the meantime. There is no single right answer, but there is a clear way to think about it.

If you apply before the investigations are complete, an insurer will often postpone a decision until the key results are in, or price cautiously on the assumption that something may yet be found, and then reassess. That is not necessarily a reason to wait — being without cover has its own risk, and applying starts the process — but it does mean you should expect a "let us see the results first" response rather than an immediate final answer. The trade-offs are set out fully in our page on applying for cover while you wait for test results.

Because insurers set their own thresholds and read cardiac histories differently, one insurer's caution is not the market's verdict. When you are ready to see where an honest account of your AF actually lands, you can get life insurance quotes and let an FCA-authorised broker place your case with the insurers most comfortable with heart rhythm conditions.

AF found by chance versus AF with symptoms

A lot of atrial fibrillation is discovered by accident — a nurse notices an irregular pulse at a routine check, or a wearable flags something, and investigation confirms AF in someone who felt entirely well. It is natural to hope that an incidental finding is treated more gently than AF that announced itself with symptoms. In underwriting terms, the route to diagnosis matters far less than what the investigations then showed.

An incidental finding still leads to the same questions about the echocardiogram, blood pressure, thyroid function and stroke risk, because those are what determine the risk regardless of how the AF came to light. Two people — one who collapsed with palpitations, one whose AF was spotted on a routine trace — can end up with identical terms if their scans, their control and their stroke-risk factors are the same. The underwriter is assessing the condition and its consequences, not the appointment where it turned up.

If your AF sits alongside other things an insurer asks about, it helps to see the whole application as one picture rather than a set of separate problems. Our guide to getting cover with a history, a condition or a job covers how a diagnosis like AF is weighed together with the rest of your history.

Scotland and Northern Ireland

The underwriting of atrial fibrillation is UK-wide: the questions, the focus on stroke risk and structural disease, and the way an anticoagulant is read do not change with your home nation. The disclosure duty under the Consumer Insurance (Disclosure and Representations) Act 2012 applies throughout the UK as well.

What differs is the statute governing your access to the medical reports the insurer relies on — and for AF, those reports matter a great deal, because so much turns on your ECG, your echocardiogram and your hospital letters. In England, Wales and Scotland, the Access to Medical Reports Act 1988 gives you the right to see a report your own doctor prepares for an insurer before it is sent, and to ask for factual errors to be corrected. In Northern Ireland, the equivalent right comes from the Access to Personal Files and Medical Reports (Northern Ireland) Order 1991. Wherever you live, use that right: an accurate cardiac report is the foundation of a fair assessment, so it is worth checking before it goes to the insurer.

Frequently asked questions

Does atrial fibrillation stop me getting life insurance?

Rarely on its own. AF is common and often well controlled, so most applications are assessed rather than refused. Underwriters weigh whether it is paroxysmal or permanent, what caused it, how well the rate or rhythm is controlled, and whether any underlying structural heart disease was found. The terms follow those specifics rather than the diagnosis itself.

Do insurers penalise me for taking an anticoagulant?

Not as a penalty. An anticoagulant tells the underwriter your clinical team judged your stroke risk high enough to warrant treatment, which is part of the picture, and it also shows the risk is being managed. Insurers usually ask which medicine you take, how long you have taken it, and whether monitoring is stable, rather than treating the drug itself as a mark against you.

Is AF found by chance treated differently?

The route to diagnosis matters less than what the investigations showed. An incidental finding at a routine check still leads to the same questions about echocardiogram results, blood pressure, thyroid function and symptoms. Insurers assess the underlying condition and its stroke risk, not the appointment where it happened to turn up.